Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > @PRC - Potential TFC-1067 - year 1-5

<< Previous

Bullboard Posts

Next >>

Post by 24minus7on Jun 26, 2022 4:24am

526 Views

Post# 34782814

@PRC - Potential TFC-1067 - year 1-5

https://1drv.ms/x/s!AvRAHt7sXjA7g64TCBfGQtgwM0Humg?e=5P3cq1

Figures from year 4 onwards suggest that AbbVie/Allergan have not only been able to serve an existing market, but have also been able to create a new NEED after a high quality and high priced treatment method (skinlightening/dyschromia).

@PRC - I look forward to seeing your numbers next Monday.

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?